This report provides comprehensive information on the therapeutic development for Tinnitus, complete with comparative analysis at various stages, therapeutics assessment by drug target.
The National Tinnitus Awareness Week along with the American Tinnitus Association (ATA) is using the occasion to raise awareness regarding the prevalence and human impact of the condition that is also referred as the “ringing of the ears” that patients suffer often to a debilitating degree. Unfortunately, till now the response towards tinnitus research has only recently gained momentum, wherein health departments and governments are finding solutions that would commensurate the size of the problem.
This report: Tinnitus - Pipeline Review, H1 2014 provides a complete overview on the therapeutic development for tinnitus. It also provides a complete comparative analysis at various stages and features even the investigational drugs from across the globe. Since tinnitus is connected to other associated conditions, it negatively impacts the quality of life led by the patient, including causing sleep disorders, social isolation, anxiety and depression. Moreover, since the financial consequences of the disease are also huge — amounting to USD 30,000 annually — patients are often wary of this problem. However, non-governmental organizations and the private sector have made promising inroads despite the condition not being a reimbursable medical condition by most health insurance companies.
Auris Medical’s Phase IIB study with AM-101 in treatment of acute inner ear tinnitus
Auris Medical announced in March 2014 that results from its Phase IIB clinical trials with AM-101 for treating the acute ear tinnitus. The trial experimented with the drug and found it to be well tolerated and safe in the treatment of the condition that arises from traumatic acoustic injury to the cochlea and otitis media parts of the ear. The clinical trial was a confirmed a success when the drug showed persistent, clinically relevant and statistically significant improvements in patients.
The tinnitus review for the AM-101 was conducted at 28 sites, including Germany, Netherlands, Poland and Belgium wherein 248 patients with acute inner ear tinnitus received three I.T. injections of either AM-101 at 0.27 or 0.81mg/mL or placebo over three consecutive days. They were then monitored for over 90 days. However, the effects of the treatment were less pronounced in patients who had bilateral rather than unilateral tinnitus since in the trials, only one ear was treated as a safety measure.
Autifony Therapeutics Initiates Phase I Study for Lead Product, AUT00063
Other than AM-101, other companies like Autifony Therapeutics are initiating Phase 1 study for their developed product AUT00063. Being evaluated for treatment of age-related hearing loss and tinnitus, the study of the drug was conducted in UK in around 60 young and elderly volunteers. The clinical trial is also exploring a variety of novel pharmacodynamic endpoints and interactions, which is expected to be completed in Q1 of 2014.
Healthcare services are realizing they need to devise drugs that will best serve the tinnitus patients. However, for the best possible approach of the tinnitus treatment research, governments also need to play a bigger role which will act as a catalyst for action and allocate resources accordingly.
For further insights,
About Research on Global Markets
Research on Global Markets is a leading source for market research on various sectors globally, offering premium research content from worldwide publishers of market research reports. Our database hosts premium market research content developed by global publishers. It offers premium industry research reports, company profiles and country briefs. We have a dedicated team of research professionals who can facilitate, in an unbiased manner, the process of identifying appropriate market research reports that are targeted to fulfill all your information-related requirements.
For more details on the content of each report and ordering information please contact:
Email: [email protected]
US: +1 800 986 6819
UK: +44 203 514 2363
India: +91 22 4098 7600
Tinnitus research, tinnitus review, tinnitus treatment research